American Society of Hematology

ASH is committed to helping practicing hematologists provide quality care to patients, continue their professional development, and enhance their knowledge and expertise.

Guidelines and Quality Care

Resources to help practicing hematologists improve the quality
of care provided to patients

Drug Resources

Newly approved therapies and access information on hematologic drugs

Consult a Colleague

Service that provides advice on clinical questions in one to two days

Professional Development

Services to support hematologists with continuing medical education and recertification

Clinical Priorities

Resources to help hematologists understand federal programs, policy developments, and relevant issues affecting clinical practice

ASH Practice Update

Email newsletter highlighting the Society's latest educational offerings and developments impacting clinicians

View all Ask the Hematologist
View all FDA alerts
  • NCATS Seeking Information on Opportunities and Challenges for Platform Vector Human Gene Therapy Trials in Rare Diseases

    The National Center for Advancing Translational Sciences (NCATS) released a request for information soliciting input on the use of viral vectors as platforms for therapeutic gene delivery to specific organs or cell types, and how such platforms might be developed most efficiently in clinical trials for the treatment of multiple diseases.

  • Congress Changes Stance on ACA Repeal and Replace

    On July 13, 2017, the U.S. Senate released an updated version of the Better Care Reconciliation Act (BCRA), legislation to repeal large provisions of the Affordable Care Act (ACA).

  • DEA Eliminates Grace Period for Registration Renewal

    Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations. 

  • CMS Announces End to Medicare Part B Drug Payment Model

    On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model.  CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.

View all policy news
back to top